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Abstract
The clinical manifestation of oncogenic osteomalacia includes bone pain, pathological fractures, general fatigue and muscle weakness. Such 
unspecific symptoms hinder the establishment of a proper diagnosis which very often requires long-lasting investigations with many 
diagnostic imaging methods. Here, we discuss difficulties in the diagnosis of oncogenic osteomalacia using the example of our own clini-
cal case: a 56 year-old woman with a history of pain in the left hip and two years of walking difficulties. A plain radiograph and CT scan 
revealed pathological fractures. Multiple myeloma, primary hyperparathyroidism and bone metastatic disease were excluded. Routine 
laboratory tests showed elevated alkaline phosphatase and a mild degree of hypophosphatemia. CT and MR imaging confirmed the 
presence of a pathological mass in the thorax. Tumour excision and histopathological test results revealed the diagnosis of a phospha-
turic mesenchymal tumour. Our case, showing the clinical course of the disease from the symptoms manifested at the beginning to the 
establishment of the diagnosis, can serve as a model illustration of the diagnostic struggle involved with oncogenic osteomalacia. (Pol 
J Endocrinol 2012; 63 (3): 234–238)
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Streszczenie
Osteomalacja onkogeniczna jest rzadkim zespołem paranowotworowym klinicznie charakteryzującym się bólami kostnymi, złamaniami 
patologicznymi, uogólnionym zmęczeniem i osłabieniem mięśniowym. Niecharakterystyczne i mało specyficzne objawy powodują, że 
postawienie właściwej diagnozy jest często bardzo trudne, czasochłonne i wymaga wielu badań dodatkowych. Autorzy omówili problemy 
i trudności diagnostyczne tej jednostki chorobowej na podstawie własnego przypadku klinicznego — 56-letniej chorej z objawami bólu 
lewego stawu biodrowego i trudnościami w poruszaniu się od około 2 lat. W RTG i tomografii komputerowej miednicy zobrazowano 
złamania patologiczne. Przeprowadzono diagnostykę różnicową w kierunku szpiczaka mnogiego, nadczynności przytarczyc i rozsiewu 
choroby nowotworowej. Podstawowe badania laboratoryjne wykazały podwyższenie aktywności fosfatazy alkalicznej i umiarkowanego 
stopnia hipofosfatemię. Badania tomografii komputerowej i rezonansu magnetycznego klatki piersiowej potwierdziły obecność masy 
patologicznej wewnątrz klatki piersiowej. Usunięcie guza i badanie histopatologiczne tkanki przyniosło rozpoznanie fosfaturycznego guza 
mezenchymalnego. Prezentowany przypadek kliniczny — od pojawiania się pierwszych objawów, poprzez proces diagnostyczny, do wyle-
czenia — może stanowić lekcje pokazową zmagań diagnostycznych w onkogenicznej osteomalacji. (Endokrynol Pol 2012; 63 (3): 234–238)
Słowa kluczowe: onkogeniczna osteomalacja, hipofosfatemia, bóle kostne, złamania patologiczne
Case report
A 56 year-old woman was referred to our Department 
of Endocrinology and Internal Medicine at the Medical 
University of Gdansk for evaluation of multiple frac-
tures.
She had had pain in her left hip for two years. The 
pain was the reason why she visited her general prac-
titioner, a neurologist and an orthopaedic consultant. 
Plain radiograph and magnetic resonance imaging 
(MRI) of the vertebrae and radiographs of the hip joints 
had been carried out, yet these imaging tests had not 
revealed the cause of her complaints. Rehabilitation 
and sanatorium treatment did not improve the patient’s 
condition. Gradually, the discomfort intensified and 
additionally pain of the lower right extremity occurred. 
A radiograph of her hip joints, taken 18 months after the 
first examination, revealed fractures of the ileum and 
superior pubic ramus on the right (Figure 1).
A CT scan of the abdominal region detected patho-
logical fractures in the 10th rib, ischiadic, pubic and iliac 
bones on the right, as well as osteolytic lesions in the 
235
Endokrynologia Polska/Polish Journal of Endocrinology 2012; 63 (3)
O
PI
S 
PR
Z
Y
PA
D
K
U
Figure 1. Frontal radiograph of the pelvis. White arrows point to 
fractures of the right ileum and superior pubic ramus
Rycina 1. Badanie RTG stawów biodrowych. Białymi strzałkami 
zaznaczono miejsca złamania górnego ramienia kości łonowej oraz 
kości kulszowej po prawej stronie
Figure 2. Abdominal CT: pathological fractures of pelvic bones and 10th rib — images A, C, E and G taken before diagnosis; images B, 
D, F, H, and I taken six months after surgical removal of the tumour in the healing phase
Rycina 2. Badanie TK: złamania patologiczne kości miednicy i X żebra; obrazy A, C, E, G  wykonane przy rozpoznaniu; obrazy B, D, 
F, H, I wykonane 6 miesięcy po zabiegu, w fazie gojenia
sacral and iliac bones, second lumbar vertebral body, 
and in the neck of the right femur; the largest being 
32 mm (Figures 2A, 2C, 2E, 2G).
The patient was hospitalised. Existing frac-
tures were initially mistaken for secondary bone 
lesions. Differential diagnoses between multiple 
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myeloma and bone metastatic disease were both ex-
cluded. The imaging tests taken during the diagnostic 
process, such as thoracic and cranial radiographs, 
thyroid, parathyroid, breast and transvaginal ultra-
sound, double contrast barium enema and upper en-
doscopy, revealed no abnormalities, and neither did 
gynaecological or neurosurgical consultations. The 
biopsy did not reveal any bone marrow infiltra-
tion, either. The trephine biopsy showed cancellous 
bone with wide trabecular spaces and hypocellular 
bone marrow with 8% of plasmocytes, without in-
filtration by non-haemopoietic neoplasms or other 
non-haemopoietic cells.
Routine laboratory tests, including complete blood 
count, coagulation tests, liver and kidney function tests 
and tumour markers — all except elevated alkaline 
phosphatase — were within reference values. The 
calcium and phosphorus balance checks for primary 
hyperparathyroidism revealed normal PTH and calcium 
levels and mild hypophosphatemia (Table I).
A technetium (99 mTc) sestamibi scan revealed 
an increased uptake in the second and third thoracic 
vertebrae, both shoulders, all ribs, ischial and iliac bones, 
the right pubic and radial bones, and both necks of the 
femur. The patient was admitted to the Department of 
Endocrinology and Internal Medicine at the Medical 
University of Gdansk.
The patient was generally in a good state. Upon 
physical examination, due to severe pain in the 
hip joints, she had difficulty walking and required 
crutches. 
For the purposes of a suspected neuroendocrine 
tumour, a chest CT scan was taken. At the level of the 
fifth vertebra, the scan disclosed a pathological mass, 
and this was confirmed in the MR imaging. The tumour, 
which was located on the level of Th4-Th6, resembled 
a neuroma (Figure 3).
The neurosurgical resection was performed. In the 
neurosurgeons’ opinion, the operated tissue showed 
the macroscopic character of a neuroma.
In anticipation of the histopathological results, and 
determined to continue diagnosing, we scheduled 
a CT-guided biopsy of bone lesions. Ten days after the 
neurosurgical treatment, unexpectedly the CT scan 
revealed hardly any osteomalatic changes, seen before. 
The only exception was the fracture of the ischial bone 
in its healing phase, poorly accessible to biopsy, mean-
ing that the biopsy was finally cancelled. Laboratory 
investigations revealed mild anaemia, a decrease in the 
calcium level, and an increase in the previously low or 
normal phosphate level (Table I).
During postoperative observation, the patient 
reported a gradual decrease in pain and a reduction 
in walking difficulties. Moreover, she started to walk 
unaided, and the clinical picture suggested a healing 
in the previously observed bone fractures.
The last piece in the jigsaw was the histopathological 
test result which provided the correct solution to this 
mysterious disease and helped us establish the final 
diagnosis. In postoperative tissues, PMT deriving from 
nerve roots was found.
Laboratory tests conducted six months after surgery 
showed calcium and phosphate compensation (Table I), 
a resolution of clinical signs with relief of pain symp-
toms, and healing in the bone fractures shown in the 
CT scan (Figures 2B, 2D, 2F, 2H, 2I).
Table I. Laboratory findings before, ten days after, and six months after neurosurgical resectioning
Tabela I. Ocena gospodarki wapniowo-fosforanowej pacjentki przed, 10 dni po oraz 6 miesięcy po zabiegu neuro-
chirurgicznym
Normal ranges Before surgery 10 days after surgery 6 months after 
surgery
Serum
Calcium [mg/dL] 8.9–10 9.07 9.2 9.9
Phosphate [mg/dL] 2.3–4.7 1.9 4.2 3.3
Parathyroid hormone [pg/mL] 15–65 47 119 31.4
Alkaline phosphatase [U/L] 40–150 217 124 –
25-hydroxyvitamin D3 [ng/mL] 19.8–60 66 4.43 –
Urine
Urine calcium [mg/dL] 2.9 0.4 9.7
Urine phosphorus [mg/dL] 15 12 40.8
Urine 24-hour calcium [mg/24h] 100–300 64 8 291
Urine 24-hour phosphorus [mg/24h] 400–1,300 330 246 1,224
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Figure 3. MRI revealed pathological mass (white arrows), most probably of a neuromal nature, penetrating through the intervertebral 
foramen into the spinal canal and the epidural space
Rycina 3. Badanie MRI: masa patologiczna (białe strzałki), najpewniej o charakterze nerwiaka, penetrująca przez otwór międzykręgowy 
do światła kanału kręgowego i przestrzeni zewnątrzoponowej
Discussion
The first description of a patient with oncogenic os-
teomalacia (OO) appeared in 1947, but at that time 
McCance [1] did not suspect any connection between 
a tumour located in the thigh and the osteomalatic le-
sions. Prader et al. [2] in 1959 first suggested the causal 
role of a tumour in osteomalacia.
The disease is clinically manifested by intense mus-
cular and bone pain, very often related to pathological 
fractures, increasing fatigue and general weakness, 
and proximal muscle myopathy. Gradually increasing 
difficulty in walking is observed, so in the final stage 
of the disease, patients require wheelchair assistance. 
The clinical signs and symptoms are so unspecific, and 
the disease itself so rare, that establishing a proper di-
agnosis takes approximately 2.5 years [3–4]. It took us 
two years from the moment our patient showed the first 
symptoms described as a pain in the left hip, right up 
until the time when the final diagnosis was established.
According to the most frequent causes of bone 
destruction, the patient was initially diagnosed with 
multiple myeloma, primary hyperparathyroidism, 
and finally with metastatic bone disease. The mild 
level of hypophosphatemia was overlooked during 
the diagnosis of primary hyperparathyroidism when 
normal calcium and PTH levels were shown in the 
calcium and phosphate balance. Similarly, the concept 
of the action of parathyroid hormone related peptide 
(PTHrP) as a causative factor of symptoms, without 
hypercalcaemia, with normal PTH level and no features 
of solid tumour mass which could eventually produce 
PTHrP in imaging tests, was rebutted in spite of existing 
hypophosphatemia.
When mild hypophosphatemia is the only abnor-
mality in estimating the calcium and phosphate bal-
ance, it should not be surprising that it can easily go 
unnoticed.
However, isolated hypophosphatemia caused by 
renal phosphate loss with deficiency of the active form 
of vitamin D, and both clinical and histological features 
of osteomalacia, is a main symptom of OO.
The main sign of OO in laboratory findings is 
hypophosphatemia. The plasma phosphate level is 
usually very low [5–7]. A decrease in 1.25(OH)2D3 level 
and hyperphosphaturia are also characteristic features 
of OO. 24-hour urine phosphorus excretion can be 
normal [8], because phosphaturia is represented by 
a decrease in the ratio of maximum rate of renal tubu-
lar reabsorption of phosphate to glomerular filtration 
rate (TmP/GFR) or tubular reabsorption of phosphate 
(TRP) [9]. It can hardly be expected that such an unu-
sual disease as OO could have been diagnosed solely 
on the basis of mild hypophosphatemia (through the 
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lack of 1.25(OH)2D3 an estimation with normal 25(OH)
D3 level and decreased phosphorus excretion in 24-hour 
urine collection).
Neurosurgeons intraoperatively assessed the tu-
mours as neuroma-like tissue. While final histopatho-
logical examination was being processed, not suspecting 
that the tumour deriving from the nerve tissue could 
be the reason for the patient’s complaints, it came as 
a surprise to us that the CT scan revealed regression of 
the bone lesions. The second assessment after surgery, 
an assessment of the calcium and phosphate balance, 
showed the results normally observed in hungry 
bone syndrome (an increase of PTH and a decrease in 
the vitamin D3 precursor). We observed a rapid bone 
demineralisation with compensation of biochemical 
disturbances, a few days or months after a tumour 
resection. These are both characteristic features of OO 
[10]. Usually, a clinical improvement is noticeable in 
the first week after the tumour resection [11]. Before 
we received the histopathological result, our patient 
reported a decrease in pain and could walk unaided.
Confirmation of the diagnosis of OO comes with 
the detection of an increased activity of phosphaturic 
factors (phosphatonins) such as fibroblast growth factor 
23 (FGF-23), matrix extracellular phosphoglycoprotein 
(MEPE), stanniocalcin, and frizzled-related protein 
4 (FRP4) [12]. The cause of an increased activity of 
FGF23 in OO is its excessive production in tumour 
cells. Similar symptoms with an excessive renal tubu-
lar phosphate loss are observed in rare genetic disor-
ders such as autosomal dominant hypophosphatemic 
rickets (ADHR) and X-linked hypophosphatemic 
rickets (XLH), both caused by mutations preventing 
FGF23 from degeneration. 
Nowadays, the diagnosis of OO may be confirmed 
through the estimation of FGF23 with commercially 
available laboratory kits. Phosphates and FGF23 levels 
become normalised just a day after tumour resection. 
That is why normalisation of phosphates level at the 
time of diagnosis proved the recognition of OO. Un-
fortunately, the estimation of FGF23 at that moment, 
without its basic assessment, was worthless from this 
diagnostic point of view.
Establishing an accurate diagnosis may be difficult. 
The first step in recognising OO is to be aware of the 
occurrence of this type of ailment. Unspecific clinical 
symptoms, and not very spectacular abnormalities in 
the laboratory findings, do not suggest a rare disease. 
Usually, imaging pathological fractures begins the diag-
nostic process which is long, laborious, and extensive. In 
basic laboratory tests, we can only expect an increased 
level in alkaline phosphatase and hypophosphatemia. 
In analysis of the calcium and phosphate balance in 
the presence of normal calcium and PTH levels, a mild 
decrease in phosphorus levels is often asymptomatic, 
and therefore unnoticeable.
We are convinced that, next time, awareness alone 
of such a rare disease will be enough to combine hy-
pophosphatemia, bone pain, fractures and long-term 
complaints into a diagnosis of OO.
We wish all readers who have studied our case report 
excellent diagnoses and rapid diagnostic processes.
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